

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) ~~Intraluminal~~ An intraluminal device, suitable for implantation in a body, which device is provided with a coating, ~~characterised in that~~ wherein the coating comprises:

50-97% heparan sulfate;
1-20% laminin; and
0.2-15% type IV collagen;
~~entaetin; and~~
~~nidogen.~~

2. (currently amended) ~~Intraluminal~~ The intraluminal device according to claim 1, ~~characterised in that~~ wherein the coating comprises:

75-95% heparan sulfate;
3-10% laminin; and
0.5-10% type IV collagen.

3. (canceled)

4. (currently amended) ~~Intraluminal~~ The intraluminal device according to claim 1, ~~characterised in that~~ wherein the coating ~~furthermore~~ further comprises a growth factor.

5. (currently amended) ~~Intraluminal~~ The intraluminal device according to claim 4, ~~characterised in that~~ wherein the growth factor is ~~chosen~~ selected from the group consisting of bFGF, IGF, TGF- β and VEGF.

6. (currently amended) ~~Intraluminal~~ An intraluminal device, suitable for implantation in a body, the device being provided with a coating that comprises:

50-97% heparan sulfate;
1-20% laminin;
0.2-15% type IV collagen; and
an antibiotic.

7. (currently amended) ~~Intraluminal~~ The intraluminal device according to claim 6, ~~characterised in that~~ wherein the antibiotic comprises gentamycine.

8. (currently amended) ~~Intraluminal~~ The intraluminal device according to claim 1, ~~characterised in that~~ wherein the coating further comprises vitronectine.

9. (currently amended) ~~Intraluminal~~ The intraluminal device according to claim 1, ~~characterised in that~~ wherein the coating comprises:

- 85-95% heparan sulfate;
- 5-6% laminin;
- 3-4% type IV collagen;
- 0.5-1.5% entactin and nidogen;
- 0.001-1% growth factors; and
- 0.001-1% antibiotic.

10. (currently amended) ~~Intraluminal~~ The intraluminal device according to claim 1, ~~characterised in that~~ wherein the intraluminal device is a prosthesis that comprises a stent or a graft.

11. (currently amended) ~~Coating~~ A coating suitable for [[a]] the intraluminal device according to claim 1.

12. (currently amended) ~~Method~~ A method for preparing [[a]] an intraluminal device, comprising the steps of:

- providing an intraluminal device for implantation in a body;
- preparing a composition, comprising, in about 50 mg/ml solvent:

50-97% heparan sulfate;

1-20% laminin;
0.2-15% type IV collagen; and
the solvent being a suitable buffer or water;
- dipping the intraluminal device in the composition;
and
- drying the dipped intraluminal device.

13. (currently amended) ~~Method~~ The method according to claim 12, ~~characterised in that~~ wherein the composition further comprises entactin and nidogen.

14. (currently amended) ~~Method~~ The method according to claim 12, ~~characterised in that~~ wherein the composition ~~furthermore~~ further comprises a growth factor, ~~chosen~~ selected from the group consisting of bFGF, IGF, TGF- β and VEGF.

15. (currently amended) ~~Method~~ The method according to claim 12, ~~characterised in that~~ wherein the composition further comprises an antibiotic.

16. (currently amended) ~~Method~~ The method according to claim 12, ~~characterised in that~~ wherein the composition further comprises vitronectin.

17. (currently amended) ~~Method~~ The method according to claim 12, ~~characterised in that~~ wherein the composition comprises:

85-95% heparan sulfate;
5-6% laminin;
3-4% type IV collagen;
0.5-1.5% entactin and nidogen;
0.001-1% growth factors; and
0.001-1% antibiotic.

18. (new) The intraluminal device according to claim 1, wherein the coating further comprises entactin and nidogen.